Literature DB >> 21932073

Infliximab induced endophthalmitis in a patient of fistulizing Crohn's disease.

Rashi Kochhar, Vishali Gupta, Usha Dutta, Kartar Singh, Rakesh Kochhar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21932073     DOI： 10.1007/s12664-011-0130-8

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN： 0254-8860


× No keyword cloud information.
  6 in total

1.  Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors:  D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal:  N Engl J Med       Date:  1999-05-06       Impact factor: 91.245

2.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

3.  Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker.

Authors:  Pankaj Kumar Agarwal; Mick Gallaghar; Elizabeth Murphy; Meena Virdi
Journal:  Indian J Ophthalmol       Date:  2007 May-Jun       Impact factor: 1.848

4.  Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes.

Authors:  Vivian Schiedler; Ingrid U Scott; Harry W Flynn; Janet L Davis; Matthew S Benz; Darlene Miller
Journal:  Am J Ophthalmol       Date:  2004-04       Impact factor: 5.258

5.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

Authors:  Jean-Frederic Colombel; Edward V Loftus; William J Tremaine; Laurence J Egan; W Scott Harmsen; Cathy D Schleck; Alan R Zinsmeister; William J Sandborn
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

6.  Infliximab maintenance therapy for fistulizing Crohn's disease.

Authors:  Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245
  6 in total
  3 in total

Review 1.  Crohn's disease in low and lower-middle income countries: A scoping review.

Authors:  Ruma Rajbhandari; Samantha Blakemore; Neil Gupta; Alma J Adler; Christopher Allen Noble; Sara Mannan; Klejda Nikolli; Alison Yih; Sameer Joshi; Gene Bukhman
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

Review 2.  Ocular adverse effects of therapeutic biologics.

Authors:  Helio V Neves da Silva; John Placide; Anne Duong; Yasmyne Ronquillo; Shannon McCabe; Majid Moshirfar
Journal:  Ther Adv Ophthalmol       Date:  2022-04-26

Review 3.  A review of ocular adverse events of biological anti-TNF drugs.

Authors:  Fernanda Nicolela Susanna; Carlos Pavesio
Journal:  J Ophthalmic Inflamm Infect       Date:  2020-04-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.